What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Hans-Joachim Schmoll mainly focuses on Internal medicine, Surgery, Colorectal cancer, Oncology and Chemotherapy.
He focuses mostly in the field of Internal medicine, narrowing it down to matters related to Gastroenterology and, in some cases, Sequela.
His Surgery study integrates concerns from other disciplines, such as Metastasis and Toxicity.
His Colorectal cancer study incorporates themes from General surgery, Fluorouracil, Radiation therapy and MEDLINE.
His study looks at the relationship between Oncology and fields such as Combination chemotherapy, as well as how they intersect with chemical problems.
His Chemotherapy research is multidisciplinary, incorporating perspectives in Nausea, Cumulative dose and Vomiting.
His most cited work include:
- Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment (894 citations)
- European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. (490 citations)
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer (474 citations)
What are the main themes of his work throughout his whole career to date?
Hans-Joachim Schmoll spends much of his time researching Internal medicine, Oncology, Colorectal cancer, Chemotherapy and Surgery.
His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology.
The Oncology study combines topics in areas such as Combination chemotherapy, Regimen, Randomized controlled trial, Disease and Bevacizumab.
His biological study spans a wide range of topics, including Adjuvant, Locally advanced and Clinical trial.
Hans-Joachim Schmoll frequently studies issues relating to Radiation therapy and Chemotherapy.
His Oxaliplatin study combines topics in areas such as Irinotecan and Adjuvant therapy.
He most often published in these fields:
- Internal medicine (58.70%)
- Oncology (43.48%)
- Colorectal cancer (30.43%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (58.70%)
- Oncology (43.48%)
- Colorectal cancer (30.43%)
In recent papers he was focusing on the following fields of study:
Hans-Joachim Schmoll mainly investigates Internal medicine, Oncology, Colorectal cancer, Bevacizumab and Oxaliplatin.
As part of his studies on Internal medicine, Hans-Joachim Schmoll frequently links adjacent subjects like Surgery.
His study in Surgery is interdisciplinary in nature, drawing from both Cancer and FOLFIRI.
The Oncology study combines topics in areas such as Fluorouracil, Disease and First line.
Hans-Joachim Schmoll combines subjects such as Adjuvant, Locally advanced, Clinical trial and Randomized controlled trial with his study of Colorectal cancer.
His study in Bevacizumab is interdisciplinary in nature, drawing from both Combination chemotherapy, Chemotherapy regimen, FOLFOX, FOLFOXIRI and Advanced colorectal cancer.
Between 2013 and 2021, his most popular works were:
- Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial (136 citations)
- Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. (92 citations)
- Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. (78 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Oncology, Colorectal cancer, Clinical trial and Oxaliplatin.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery.
His studies deal with areas such as Bevacizumab, Fluorouracil, Survival rate and Hazard ratio as well as Oncology.
His Colorectal cancer study combines topics from a wide range of disciplines, such as Meta-analysis, Predictive value of tests, Survival analysis and Chemotherapy.
His Clinical trial research is multidisciplinary, incorporating elements of Receptor, Tolerability, Immunology and Performance status.
Hans-Joachim Schmoll usually deals with Oxaliplatin and limits it to topics linked to Capecitabine and Locally advanced and Radiology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
